203640-02-2

Basic information

• Product Name: (R)-3-(1H-Indol-3-yl)-2-[4-(2-phenyl-2H-tetrazol-5-yl)-benzenesulfonylamino]-propionic acid benzyl ester
• Synonyms: (R)-3-(1H-Indol-3-yl)-2-[4-(2-phenyl-2H-tetrazol-5-yl)-benzenesulfonylamino]-propionic acid benzyl ester
• CAS NO: 203640-02-2
• Molecular Weight: 578.651
• Mol File: 203640-02-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (R)-3-(1H-Indol-3-yl)-2-[4-(2-phenyl-2H-tetrazol-5-yl)-benzenesulfonylamino]-propionic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-(1H-Indol-3-yl)-2-[4-(2-phenyl-2H-tetrazol-5-yl)-benzenesulfonylamino]-propionic acid benzyl ester(203640-02-2)
• EPA Substance Registry System: (R)-3-(1H-Indol-3-yl)-2-[4-(2-phenyl-2H-tetrazol-5-yl)-benzenesulfonylamino]-propionic acid benzyl ester(203640-02-2)

Safety Data

• Hazardous Substances Data: 203640-02-2(Hazardous Substances Data)

Upstream product

• 126090-33-3 (R)-2-tert-Butoxycarbonylamino-3-(1H-indol-3-yl)-propionic acid benzyl ester 
• 99504-75-3 5-(4-bromophenyl)-2-phenyl-2H-tetrazole 
• 203639-66-1 4-(2-Phenyl-2H-tetrazol-5-yl)-benzenesulfonyl chloride 

Downstream Products

• 193809-84-6 (R)-3-(1H-Indol-3-yl)-2-[4-(2-phenyl-2H-tetrazol-5-yl)-benzenesulfonylamino]-propionic acid 

Relevant articles and documents

Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives

Various N-sulfonylamino acid derivatives were synthesized and evaluated for their in vitro and in vivo activities to inhibit type IV collagenase (MMP-9 and MMP-2). When the amino acid residue and the sulfonamide moiety were modified, their inhibitory activities were greatly affected by the structure of the sulfonamide moiety. A series of aryl sulfonamide derivatives containing biaryl, tetrazole, amide, and triple bond were found to be potent and highly selective inhibitors of MMP-9 and MMP-2. In addition, these compounds were orally active in animal models of tumor growth and metastasis. These results revealed the potential of the N-sulfonylamino acid derivatives as a new type of candidate drug for the treatment of cancer.